NICE(UK): Venetoclax plus obinutuzumab can be used, within its marketing authorisation, as an option for untreated chronic lymphocytic leukaemia (CLL) in adults. It can only be used if… read more.
People who have experienced childhood sexual abuse have twice the odds of receiving a cancer diagnosis at age 65 or older compared to others who have not experienced… read more.
A new study funded by the National Cancer Institute at the National Institutes of Health finds that how high school students perceive the costs of sun protection and the rewards of tanning… read more.
Advances in cancer treatment mean more people are living longer after a cancer diagnosis. But some survivors develop lymphedema—long-term swelling in the arms, hands, legs or feet that… read more.
Researchers have already shown that mild to moderate exercise can reduce “chemo brain,” and a new study suggests that a low dose of an over-the-counter anti-inflammatory, ibuprofen, can… read more.
The antidepressant duloxetine does not appear to prevent chemotherapy-associated nerve damage in colorectal cancer. This finding appeared in the JCO Oncology Advances on March 25, 2026 followed by… read more.
NICE(UK): Belantamab mafodotin plus pomalidomide and dexamethasone can be used as an option to treat multiple myeloma in adults, if: i) they have only had 1 line of treatment… read more.
The FDA approved Boehringer Ingelheim’s Hernexeos (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase… read more.
Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research. The findings are presented today… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has approved imlunestrant tosylate (Inluriyo), a new treatment for adult patients with a certain type of breast… read more.
The company’s partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziiher (zanidatamab-hrii) at the American Association for Cancer Research (AACR) Annual Meeting, being… read more.
Hematology-oncology trained physicians who treat sickle cell disease reported higher rates of burnout (60%) than their counterparts who do not provide sickle cell care (43%) despite no differences in grit and resilience between the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
